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Abstract Anti-vascular endothelial growth factor (VEGF)
therapies have improved clinical outcomes for patients
with cancers and retinal vascular diseases. Three anti-
VEGF agents, pegaptanib, ranibizumab, and aflibercept,
are approved for ophthalmic indications, while beva-
cizumab is approved to treat colorectal, lung, and renal
cancers, but is also used off-label to treat ocular vascular
diseases. The efficacy of bevacizumab relative to ranibi-
zumab in treating neovascular age-related macular degen-
eration has been assessed in several trials. However,
questions persist regarding its safety, as bevacizumab can
form large complexes with dimeric VEGF165, resulting in
multimerization of the Fc domain and platelet activation.
Here, we compare binding stoichiometry, Fcc receptor
affinity, platelet activation, and binding to epithelial and
endothelial cells in vitro for bevacizumab and aflibercept,
in the absence or presence of VEGF. In contrast to beva-
cizumab, aflibercept forms a homogenous 1:1 complex with
each VEGF dimer. Unlike multimeric bevacizumab:VEGF
complexes, the monomeric aflibercept:VEGF complex does
not exhibit increased affinity for low-affinity Fcc receptors,
does not activate platelets, nor does it bind to the surface of
epithelial or endothelial cells to a greater degree than
unbound aflibercept or control Fc. The latter finding reflects
the fact that aflibercept binds VEGF in a unique manner,
distinct from antibodies not only blocking the amino acids
necessary for VEGFR1/R2 binding but also occluding the
heparin-binding site on VEGF165.
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Introduction
Angiogenesis, the growth of new blood vessels from pre-
existing vasculature, is a highly orchestrated process that is
critical for proper embryonic and postnatal vascular
development [1]. Abnormal or pathological angiogenesis is
a hallmark of cancer and several retinal diseases where the
upregulation of proangiogenic factors, such as vascular
endothelial growth factor (VEGF) and placental growth
factor (PlGF), leads to increases in endothelial prolifera-
tion, changes in vasculature morphology, and increased
vascular permeability [2, 3]. In particular, blockade of
VEGF has shown clinical utility in the oncology setting as
well as several retinal vascular diseases characterized by
abnormal angiogenesis and/or vascular permeability, such
as the ‘‘wet’’ form of age-related macular degeneration
(AMD), the leading cause of blindness in the elderly [4, 5].
The formation of new blood vessels and vascular leakage
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in wet AMD leads to macular edema, thickening of the
retina, and loss of vision. Elevated levels of VEGF have
been found in the vitreous fluid and retinal vasculature of
patients with AMD [6]. Blocking VEGF activity has also
become the therapy of choice for treating diabetic macular
edema (DME), retinal vein occlusions, and other ocular
diseases where abnormal angiogenesis is the underlying
etiology [7–10].
Several anti-VEGF therapies have been approved for
use in neovascular or ‘‘wet’’ AMD. Pegaptanib, an
oligonucleotide aptamer that binds the heparin-binding
domain of VEGF165, was the first anti-VEGF therapy that
showed some benefit in treating wet AMD, although most
patients still experienced visual decline [11]. The intro-
duction of ranibizumab, an affinity-matured, humanized
monoclonal antibody fragment (Fab), represented a major
advance in treating wet AMD patients since it was not only
able to stabilize but in many cases improve visual acuity
[12]. However, prior to regulatory approval of ranibizu-
mab, ophthalmologists began using bevacizumab, a
humanized monoclonal antibody to VEGF already
approved for metastatic colorectal cancer, to treat wet
AMD. Like ranibizumab, bevacizumab binds to all iso-
forms of VEGF-A, but is aliquoted and repackaged for off-
label use in ophthalmological indications [13]. Several,
small, non-randomized studies evaluated bevacizumab as a
potential treatment option in the treatment for wet AMD
and thus began the ongoing debate on the merits of uti-
lizing bevacizumab for the treatment for diseases affecting
the ocular vasculature [14]. More recently, in a large
(n = 1208), prospective, randomized comparison of age-
related macular degeneration treatments trial (CATT),
comparison of the same regimens of ranibizumab or
bevacizumab demonstrated similar improvements for the
primary end point of visual acuity at 1 year [15]. However,
somewhat higher rates of systemic serious adverse events
(SAEs) were observed in patients treated with beva-
cizumab compared to ranibizumab. Curiously, the excess
in systemic SAEs observed in bevacizumab-treated
patients in the CATT trial did not correspond to adverse
cardiovascular events, such as hypertension and arterio-
thrombolic events (ATEs), previously known to be caused
by systemic VEGF inhibition in oncology trials that
employed much higher, intravenous doses of bevacizumab.
Rather, patients treated intravitreally with low-dose beva-
cizumab exhibited increases in SAEs affecting other organ
systems, particularly gastrointestinal disorders. While two
additional, but smaller trials (IVAN; n = 610, MANTA;
n = 321) individually showed no statistically significant
differences in systemic SAEs between ranibizumab and
bevacizumab [16, 17], a recent meta-analysis (n = 3665)
comprising the above studies as well as six additional trials
also found a higher incidence of gastrointestinal disorders
in patients treated with intravitreal bevacizumab compared
to ranibizumab, with no differences in other systemic SAEs
[18]. In comparing the safety profile of ranibizumab to
bevacizumab when treating DME, the recent Protocol T
trial showed no differences in the rates of serious adverse
events among all three anti-VEGF treatments (aflibercept,
bevacizumab, ranibizumab), though visual acuity gains
with aflibercept were significantly greater than with rani-
bizumab or bevacizumab in the overall population, and
these differences were especially evident in patients with
poor vision at the start of treatment [19].
Although mechanisms underlying the potentially higher
rate of systemic SAEs not typically associated with anti-
VEGF activity in patients receiving intravitreal beva-
cizumab remains unknown, a number of investigators have
pointed out several fundamental differences between rani-
bizumab and bevacizumab. First, ranibizumab is a Fab
fragment and is significantly smaller in size than a full-
length antibody. This was advantageous for the develop-
ment for intravitreal injection as the smaller size of rani-
bizumab was expected to enhance diffusion from the
vitreous into the retina and choroid [20]. VEGF and closely
related molecules are ligands for a family of related
receptor tyrosine kinases (VEGFRs), and as such exist
naturally as dimers. Since ranibizumab is a Fab fragment,
two molecules of ranibizumab are bound by each VEGF
dimer. In contrast, bevacizumab is an IgG comprising two
Fabs as well as an Fc domain. Due to its bivalent nature, a
single bevacizumab molecule can bind both active sites in
a single VEGF dimer. Interestingly, it has also been
reported that bevacizumab has the capacity to form large
multimeric complexes with VEGF [21, 22]. Second,
though derived from bevacizumab, ranibizumab has been
affinity-matured with a reported affinity enhancement of
10- to 100-fold relative to the Fab, which is associated with
a similarly enhanced activity of ranibizumab in cell-based
assays, compared to the Fab fragment of bevacizumab
[23, 24]. However, the bivalent nature of the full-length
bevacizumab antibody contributes substantially to its
ability to bind and neutralize VEGF. Specifically, avidity
interactions of bevacizumab with its dimeric VEGF target
significantly increase binding affinity and potency of the
bivalent antibody relative to the monovalent antigen-
binding fragment [25]. Lastly, ranibizumab does not con-
tain a fragment crystallizable (Fc) region, unlike full-length
antibodies. While the Fc moiety is useful to increase cir-
culatory half-life when an antibody is given systemically,
via its interactions with the neonatal receptor, the Fc region
can also promote effector function if the antibody is mul-
timerized upon binding to its target. In the absence of this
multimerization, the Fc domain of therapeutic antibodies
rarely occupies Fcc receptors due to the constant compe-
tition with high levels of endogenous IgG (5–15 g/L) [26].
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Meyer et al. [22] have shown that bevacizumab and
equimolar amounts of VEGF165 can form immune-like
complexes, which in the presence of heparin can engage
the FccRIIa receptor on thrombocytes leading to platelet
activation. Other studies have also reported differences in
the activities of ranibizumab and bevacizumab that appear
to be unrelated to VEGF neutralization per se. For exam-
ple, bevacizumab exhibits enhanced binding to and accu-
mulation in retinal pigment epithelium (RPE) cells in vitro,
relative to ranibizumab [27].
Aflibercept is a novel soluble decoy receptor consisting
of an all-human amino acid sequence comprising the
second Ig domain of human VEGFR1 and the third Ig
domain of human VEGFR2 expressed as an inline fusion
with the constant region (Fc) of human IgG1 [28]. Like
bevacizumab and ranibizumab, aflibercept binds all forms
of VEGF-A (VEGF) but in addition binds PlGF and
VEGF-B [25]. Aflibercept was recently approved for the
treatment for wet AMD based on the VIEW studies [29].
These trials demonstrated equivalent improvements in
visual acuity at 1 year between patients treated monthly
with ranibizumab and those treated with aflibercept every
other month following three initial monthly loading doses.
Each aflibercept molecule, like bevacizumab, contains
two, independent VEGF binding arms held together via
the Fc moiety. Upon binding VEGF dimers, aflibercept
could in theory form large, multimeric immune-like
complexes similar to those previously described for
bevacizumab, which in turn could trigger processes
mediated by low-affinity Fc receptors.
In the present study, we compare the binding stoi-
chiometries of bevacizumab and aflibercept to VEGF165,
over a range of relative molar concentrations, and also
assessed the binding affinities of bevacizumab and
aflibercept to VEGF121, VEGF165, and Fcc receptors, alone
or when complexed with VEGF. The ability of beva-
cizumab:VEGF and aflibercept:VEGF complexes to acti-
vate human platelets in vitro, and the propensity of both
bevacizumab and aflibercept to bind to cultured human
retinal epithelial (ARPE-19) and human umbilical vein
endothelial cells (HUVEC) in the presence and absence of
VEGF165 and VEGF121 also were assessed. The results of
these experiments confirm that bevacizumab can form
large multimeric complexes with VEGF, when both anti-
body and ligand are present in roughly (within tenfold)
equimolar concentrations. In contrast, aflibercept forms a
homogenous 1:1 complex with VEGFs over all molar ratios
tested. Moreover, in contrast to the large and heterogenous
bevacizumab:VEGF165 complexes, these discrete afliber-
cept:VEGF165 complexes do not activate platelets in the
presence of heparin. Finally, aflibercept does not bind to
the surface of HUVEC or ARPE-19 cells to an appreciably
greater degree than the control, human Fc (hFc), in the
presence or absence of VEGFs. In contrast, binding of
bevacizumab to the surface of these cells was greatly
enhanced in the presence of exogenous or endogenous
VEGF165, but not VEGF121. This finding suggested that the
cell surface binding of bevacizumab:VEGF165 complexes
was mediated by the heparin and/or neuropilin-1 (NRP1)-
binding domains of this VEGF isoform. This was con-
firmed by subsequent surface plasmon resonance (Biacore)
experiments, which showed that bevacizumab:VEGF165
complexes, but not aflibercept:VEGF165 complexes, were
readily bound by surface-captured NRP1 or heparin. In
conclusion, under certain conditions, bevacizumab can
form large, multimeric immune-like complexes that
exhibit enhanced binding not only to a range of Fcc
receptors, but also, when complexed with VEGF165, to
heparin and neuropilin present on the surfaces of cells. In
contrast, aflibercept exclusively forms a 1:1 complex with
VEGF dimers, which does not appreciably increase
binding to low-affinity Fc receptors, heparin, or neu-
ropilin—compared to unbound aflibercept or control,
monomeric IgGs. The fundamental difference between
bevacizumab and aflibercept behavior appears to be
attributable to the unique way in which the aflibercept
encompasses or ‘‘Traps’’ a single, VEGF dimer, not only
blocking the amino acids necessary for VEGFR1/R2
binding but also occluding the heparin-binding site on
VEGF as well.
Results
In contrast to bevacizumab, aflibercept forms a 1:1
complex with VEGF
Multiple-angled laser light scattering (MALLS) coupled
to size exclusion chromatography (SEC) was used to
calculate the stoichiometry of bevacizumab:VEGF165 and
aflibercept:VEGF165 complexes. VEGF165 was mixed
with either bevacizumab or aflibercept in solution at
molar ratios of inhibitor to ligand of between 5:1 and 1:5.
Bevacizumab was found to form a heterogeneous mixture
of multimeric complexes in the presence of VEGF165,
with molar masses ranging from *330 to 700 kDa
(Fig. 1a). In contrast, aflibercept at a 1:5 molar ratio
showed two discrete peaks (Fig. 1b), as expected based on
previous results [21]. The earlier eluting peak, with an
apparent molar mass of 157 kDa, corresponded to a 1:1
complex between aflibercept (*115 kDa) and VEGF165
(*40 kDa). The latter eluting peak corresponded to the
expected excess of free VEGF165 dimer (based on the
average molar mass of the peak and comparison with the
elution times from VEGF165 injections). Analysis of a
preformed aflibercept:VEGF165 complex at a 5:1 molar
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ratio showed a single peak of 119 kDa (Fig. 1b), which is
attributed to incomplete separation between the 1:1
aflibercept:VEGF165 complex (*157 kDa) and the excess
free aflibercept (*115 kDa).
SEC–MALLS analysis was also used to estimate the
binding stoichiometry and molar mass of the complexes
formed between bevacizumab or aflibercept and PlGF-2
(Figure S1). No complex formation was observed between
bevacizumab and PlGF-2 (Figure S1A). The afliber-
cept:PlGF-2 complex demonstrated a very similar stoi-
chiometry to the aflibercept:VEGF165 complex, with a
single major homogenous peak (molar mass of 150 kDa)
corresponding to a 1:1 complex between aflibercept and
PlGF-2 (*42 kDa) and a minor peak corresponding to an
excess of free PlGF-2 dimer (Figure S1B).
Aflibercept’s binding half-life to Fcc receptors does
not change in the presence of VEGF
Surface plasmon resonance was used to determine the
dissociation rate constants (kd) of bevacizumab and
aflibercept to the family of human Fcc receptors in the
presence or absence of VEGF165 or VEGF121 (Table 1).
Equilibrium binding constants (KD = kd/ka) were not cal-
culated since the heterogenous nature of the beva-
cizumab:VEGF complex did not allow accurate molar
concentrations to be utilized and thus association rate
constants (ka), which are dependent on concentration, could
not be determined. Bevacizumab and aflibercept, in the
absence of VEGF, exhibited the expected rapid dissocia-
tion rate constant (kd) from low-affinity Fc receptors, with
Fig. 1 Aflibercept forms 1:1




complexes were analyzed by
multi-angle laser light scattering
detection coupled to SEC. The
differential refractive index
(right y axis) and the measured
molar mass (left y axis) of peaks
are indicated as a function of
elution volume for each sample.
The experimentally determined
molar masses are indicated by
horizontal lines. Cartoons of
free VEGF165 and complexes of
aflibercept or bevacizumab
bound to VEGF165 are shown.
Complexes of VEGF165 with
bevacizumab (a) or aflibercept
(b) at various molar ratios were
incubated for 12 h at ambient
temperature. Following
incubation, the samples were
kept at 4 C in the autosampler
prior to injection
(*100–200 lg per sample)
onto a Superose 12 column pre-
equilibrated in 10 mM
phosphate containing 500 mM
NaCl buffer (pH 7.0) with a
flow rate of 0.3 mL/min.
Chromatograms of VEGF165
and bevacizumab (a) or
aflibercept (b) are superimposed
to indicate the elution profiles of
the unbound proteins. The 1:1
molar ratio complexes yielded
similar elution profiles and are
not shown for the purposes of
clarity
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t1/2 values typical for unbound endogenous IgG1 and
recombinant molecules containing IgG1-Fc
(KD & 1–10 lM) [30]. However, when bevacizumab was
pre-incubated in a 1:1 molar ratio with VEGF165 or
VEGF121, the resulting complexes exhibited longer t1/2
values (slower dissociation rate constants) when bound to
the low-affinity Fcc receptors FccRIIa, FccRIIb, FccRIIIa
(176F), FccRIIIa (176 V), and FccRIIIb compared to
bevacizumab alone. This increase in binding half-life
ranged from a ninefold increase when the beva-
cizumab:VEGF complex was flowed over FccRIIIa
(176 V) to a 177-fold increase in t1/2 when flowed over
FccRIIb. In contrast, aflibercept with or without VEGF
present exhibited no change in t1/2 values when bound to
Fcc receptors. Representative sensorgrams of beva-
cizumab and aflibercept binding to Fcc receptors are
shown in Figures S2, S3, S4.
Aflibercept:VEGF165 complexes do not activate
platelets
Previous studies have demonstrated that, in the presence of
heparin, bevacizumab:VEGF165 complexes can activate
human platelets via FccRIIa [22]. The potential for
aflibercept-VEGF165 complexes to induce FccRIIa-depen-
dent platelet activation was tested using light aggregome-
try. Preformed complexes of aflibercept and VEGF165 at
equal molar ratios in the presence of heparin failed to
induce aggregation of human platelets (Fig. 2a). In con-
trast, preformed complexes of bevacizumab and VEGF165
at equal molar ratios in the presence of heparin caused
marked aggregation of platelets over a concentration range
of 100–400 nM (Fig. 2b). However, increasing the molar
excess of bevacizumab (Cfourfold relative to VEGF165)
results in a loss of platelet activation (data not shown)
Bevacizumab:VEGF complexes below 100 nM did not
activate platelets. Platelet activation was not detected at
concentrations below 100 nM of bevacizumab:VEGF165
complex.
Platelet activation was also tested using a serotonin
release assay. The combination of aflibercept and VEGF165
at equal molar ratios (500 nM each) in the presence of
heparin was unable to stimulate serotonin release from
platelets (Fig. 2c). However, the presence of bevacizumab
and VEGF165 at an equal molar ratio of 500 nM each in the
presence of heparin induced up to 80 % release of sero-
tonin from platelets (Fig. 2d), consistent with findings from
the light aggregometry assays.
Table 1 In vitro binding affinity of bevacizumab and aflibercept for Fcc receptors in the presence and absence of VEGF121 and VEGF165


















Bevacizumab – 7.49E-04 925 1 1.11E-01 6 1 1.79E-01 4 1
VEGF165 2.41E-04 2874 3 1.02E-03 681 114 9.80E-04 707 177
VEGF121 2.03E-04 3419 4 1.42E-03 487 81 1.82E-03 380 95
Aflibercept – 7.21E-04 961 1 2.24E-01 3 1 2.55E-01 3 1
VEGF165 6.17E-04 1123 1 2.05E-01 3 1 1.74E-01 4 1


















Bevacizumab – 8.03E-03 86 1 6.26E-02 11 1 1.96E-01 4 1
VEGF165 7.78E-04 891 10 1.30E-03 533 48 1.50E-03 463 116
VEGF121 9.09E-04 762 9 1.83E-03 378 34 2.61E-03 265 66
Aflibercept – 7.62E-03 91 1 4.89E-02 14 1 1.71E-01 4 1
VEGF165 6.14E-03 113 1 3.92E-02 18 1 1.64E-01 4 1
VEGF121 5.73E-03 121 1 3.61E-02 19 1 1.42E-01 5 1
a Fold = t1/2 (ligand ? VEGF inhibitor complex)/t1/2 (VEGF inhibitor alone)
b FccRIIa allele studied was 131R
c FccRIIIa allele studied was 176V
d FccRIIIa allele studied was 176F
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Aflibercept:VEGF165 complexes do not induce
thrombocytopenia or thrombosis in FccRIIa
transgenic mice
Injection of preformed (1:1 molar) bevacizumab:VEGF165
complexes along with unfractionated heparin into trans-
genic mice expressing human FccRIIa has been reported to
cause severe thrombocytopenia and occlusive thrombosis
in alveolar capillaries [22]. We sought to determine whe-
ther preformed aflibercept:VEGF165 complexes in the
presence of unfractionated heparin could trigger a similar
set of sequelae in human FccRIIa transgenic mice. Animals
receiving aflibercept:VEGF165 complexes (1:1 molar ratio)
did not exhibit these symptoms (n = 10). Platelet counts
10 min following immune complex injection demon-
strated thrombocytopenia in animals receiving beva-
cizumab:VEGF165 but not aflibercept:VEGF165 complexes
(Fig. 3a). Specifically, mice injected with phosphate-buf-
fered saline (PBS; n = 5) had baseline platelet counts of
(1173 ± 179; mean ± SD), whereas animals receiving
bevacizumab ? VEGF165 had mean platelet counts of
331 ± 217 (with heparin; P\ 0.001) and 725 ± 303
(without heparin; P\ 0.003). Mice receiving afliber-
cept ? VEGF165 had mean platelet counts of 966 ± 168
(with heparin) and 878 ± 250 (without heparin), which
were not statistically different from baseline (PBS) animal
Fig. 2 Aflibercept:VEGF165 complexes do not activate platelets
in vitro. a Preformed equal molar (200 nM) aflibercept:VEGF165 or
bevacizumab:VEGF165 complexes were added to primed (1 lM
epinephrine), washed platelets containing 200 nM UFH unfraction-
ated heparin and percent light transmittance monitored at 600 nm.
Thrombin (1 nM, Chrono-PAR) acted as the positive control. b A
range (400–50 nM) of preformed equal molar bevacizumab:VEGF165
complexes were added to primed, washed platelets containing UFH
unfractionated heparin and percent light transmittance monitored. A
similar experiment using aflibercept:VEGF165 complexes did not
activate platelets (data not shown), and thus, only data for the 200 nM
complex (a) are shown. Serotonin release was measured from
platelets stimulated in the presence of a range of concentrations
(0.1, 0.2, 0.5 or 1.0 lM) of UFH with aflibercept:VEGF165 complex
(c) or bevacizumab:VEGF165 complex (d). Inhibitor:ligand complex
concentration was 500 nM
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counts. Mouse antihuman CD-40 ligand immune com-
plexes [22] served as a positive control and induced severe
thrombocytopenia in FccRIIa transgenic mice with mean
platelet counts of 163 ± 137 (P\ 0.001).
Consistent with the thrombocytopenia, mice injected
with bevacizumab:VEGF165 complexes developed abun-
dant occlusive thrombi in the pulmonary vasculature
(Fig. 3c). In contrast, mice injected with afliber-
cept:VEGF165 complexes failed to develop microvascular
thrombosis (Fig. 3d).
Aflibercept exhibits no significant cell surface
binding to ARPE-19 cells or HUVEC
Cell surface binding of aflibercept and bevacizumab alone
or in complex with VEGF was tested using ARPE-19
(Fig. 4a) and HUVEC (Fig. 4b). Binding studies were
conducted for both inhibitors with no ligand present or
following pre-incubation with VEGF121 or VEGF165.
Binding to ARPE-19 cells was not observed for beva-
cizumab or aflibercept in complex with VEGF121 or in the
absence of ligand (Fig. 4a, row 1, 3), but significant ARPE-
19 cell surface binding was observed for beva-
cizumab:VEGF165 complexes. Binding was not observed
for the aflibercept:VEGF165 complex (Fig. 4a, row 2).
Similarly, binding to HUVEC was not observed for
aflibercept or bevacizumab in complex with VEGF121 or in
the absence of ligand (Fig. 4b, row 1, 3). However, sig-
nificant HUVEC cell surface binding was observed for
bevacizumab:VEGF165 complexes, and only very low
levels of surface binding were observed for afliber-
cept:VEGF165 complexes (Fig. 4B, row 2). Complexes
binding to the cell surface of both ARPE-19 and HUVEC
were found to be dependent on the molar ratio of the
Fig. 3 Aflibercept ? VEGF165 ? unfractionated heparin (UFC)
complexes do not activate platelets in vivo. B6;SJL-Tg
(FccRIIa)11Mkz (FCGR2A) mice were injected with PBS (n = 5)
or preformed immune complexes (n = 10 per group) via the tail vein.
Ten minutes after reagent injection, mice were anesthetized, blood
was collected by cardiac puncture, and platelet counts were measured
using an automated cell counter. Following blood draws, animals
were killed and lungs were dissected, rinsed, and embedded in
paraffin. Paraffin blocks were sliced, and cut sections (2 lm thick)
were deparaffinized, rehydrated, and stained. Shown are platelet
counts per individual FccRIIa animal by treatment group (a) along
with representative H&E microscopy sections for PBS (b) beva-
cizumab (Bev) ? VEGF165 ? heparin (c) and aflibercept ?
VEGF165 ? heparin (d). The horizontal line in (a) represents approx-
imately 60 % of reduction from baseline mean platelet count.
Microscopy images were captured at 9200 magnification. Insets
represent 9700 magnification
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Fig. 4 Aflibercept does not
exhibit significant cell surface
binding to ARPE-19 and
HUVEC. Cell surface binding
of aflibercept and bevacizumab
was evaluated using ARPE-19
(a) and HUVEC (b). Cells were
pre-seeded on collagen-coated
96-well plates. ARPE-19 cells
were incubated with 5 nM
bevacizumab or aflibercept
alone or in the presence of
10 nM VEGF165 or 10 nM
VEGF121 at 37 C for 1 h.
HUVEC were incubated with
15 nM bevacizumab or
aflibercept alone or in the
presence of 10 nM VEGF165 or
10 nM VEGF121 at 37 C for
1 h. Surface-bound inhibitor
was detected by incubation with
A488-anti-hIgG (Fc-specific) at
4 C. Cells were washed, fixed
with 4 % paraformaldehyde,
and counterstained with a
nucleic acid counterstain (DAPI
for ARPE-19 or DRAQ5 for
HUVEC, red fluorescence) prior
to analysis. Cell surface binding
was evaluated with secondary
antibody alone (left column),
bevacizumab (middle column)
or aflibercept (right column) in
the presence of VEGF121 (a–c),
VEGF165 (d–f) or no ligand (g–
i). Scale bar = 50 lm in
(a) and 100 lm in (b)
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inhibitor:VEGF165 complex mixtures (Figure S5 and Fig-
ure S6). Complexes binding to the cell surface of ARPE-19
were observed at bevacizumab:VEGF165 ratios between
0.06:1 and 4.5:1, with the greatest binding seen at a molar
ratio of 0.1:1, and complex binding to HUVEC was
observed at bevacizumab:VEGF165 ratios between 0.5:1
and 13.5:1, with maximal binding observed at a 1.5:1
molar ratio.
Cell surface binding of bevacizumab:VEGF165
complexes is dependent on heparin in ARPE-19 cells
and neuropilin-1 in HUVEC
Cell surface binding of bevacizumab:VEGF165 complexes
was tested in the presence of heparin or recombinant
human neuropilin-1 (rhNRP-1). Pre-binding of VEGF165
with soluble heparin concentrations of 250 nM or higher
prevented binding of bevacizumab:VEGF165 complexes to
ARPE-19 cells (Fig. 5a). No significant blocking of beva-
cizumab:VEGF165 complex binding to ARPE-19 cells was
observed with concentrations of rhNRP-1 of up to 100 nM
(Fig. 5a). In contrast, pre-binding of VEGF165 with rhNRP-
1 (25 nM or higher) prevented binding of beva-
cizumab:VEGF165 complexes to HUVEC (Fig. 5b), while
no significant blocking of bevacizumab:VEGF165 complex
binding to HUVEC was observed in the presence of up to
1000 nM soluble heparin (Fig. 5b). These results are con-
sistent with surface plasmon resonance analysis of beva-
cizumab:VEGF165 and aflibercept:VEGF165 in the presence
of rhNRP-1 and heparin (Fig. 6a, b, S7A and B). Beva-
cizumab:VEGF165 complexes were found to bind to both
rhNRP-1- and heparin-coated surfaces at concentrations as
low as 1 nM. Binding of aflibercept:VEGF165 complexes to
rhNRP-1- and heparin-coated surfaces was only detected at
complex concentrations of 100 nM or greater.
Cell surface binding is dependent
on the concentration of endogenous VEGF165
ARPE-19 cells were used to test cell surface binding of
bevacizumab and aflibercept in the presence of VEGF
endogenously produced by these cells. ARPE-19 cells have
been shown to express VEGF after several days in culture
[31]. Cells in culture were incubated with aflibercept,
bevacizumab, or hFc, for 3 days starting at day 2, 4, 9, and
14, and surface binding was then examined 3 days later.
Aflibercept and the hFc control showed minimal surface
binding at all time points. In contrast, bevacizumab showed
significant cell surface binding at the Day 9–12 and Day
14–17 time points (Fig. 7c–l and 7d–1).
Next-generation sequencing and ELISA binding were
used to determine the expression level and identity of the
VEGF isoforms present in the culture medium at various
time points. VEGF165 was found to be the predominant
VEGF species present (Fig. 7m, n), with the concentration
of this isoform increasing as a function of ARPE-19 time in
culture. The highest concentrations of VEGF165 were found
on the Day 9 and Day 28 time points, consistent with the
high level of bevacizumab cell surface binding at later time
points. These results closely resemble cell surface binding
studies conducted with preformed bevacizumab:VEGF165
complexes and suggest that bevacizumab can sponta-
neously form multimeric complexes in the presence of
endogenous VEGF165.
Discussion
Several reports have indicated that bevacizumab, in con-
trast to ranibizumab, can bind cell surface-bound VEGF on
RPE and endothelial cells [27, 32]. Additional studies have
provided evidence that bevacizumab not only binds cell-
surface-bound VEGF on RPE cells, but that this binding
may trigger the complement cascade resulting in cell death
[3, 33]. Components of the complement pathway are
known to play a role in AMD pathogenesis, although the
mechanism has not been clearly defined. Activation of the
complement cascade can result in damage to retinal cells as
well as surrounding tissue [34], and conversely, comple-
ment components can contribute to neuronal homeostasis
in the retina [35]. Aflibercept, like bevacizumab, contains
an Fc domain; however, several reports have shown that
this anti-VEGF agent does not induce changes in cell
morphology, induce apoptosis, or decrease cell viability of
retinal cells in culture [36, 37].
To further understand what could be driving these
observed differences in vitro, we conducted a detailed
analysis of bevacizumab and aflibercept when complexed
with VEGF by analyzing their stoichiometry of binding,
affinity to Fcc receptors, propensity to activate platelets
and ability to bind ARPE-19 and HUVEC. The results of
these experiments demonstrate that in contrast to beva-
cizumab, which can form large multimeric complexes with
VEGF, aflibercept forms a homogeneous 1:1 molar com-
plex with VEGF and PlGF. The discrete monomeric
complexes of aflibercept:VEGF do not allow avidity-driven
Fc to Fcc receptor interactions as seen with the large
heterogeneous complexes that bevacizumab forms with
VEGF when both are present at near equal molar ratios.
Furthermore, since bevacizumab, unlike aflibercept, does
not block heparin binding to VEGF165, these multimeric
bevacizumab:VEGF complexes, in the presence of heparin,
can activate FccRIIa receptors triggering platelet aggre-
gation. Lastly, this fundamental difference in binding
geometry explains the observations that no significant cell
binding was observed for aflibercept:VEGF complexes,
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while the heterogeneous bevacizumab:VEGF complexes
bound to the cell surfaces of both ARPE-19 and HUVEC.
This report demonstrates at molar ratios of 5:1 to 1:5,
aflibercept to VEGF165, aflibercept was observed to form a
1:1 molar complex. In contrast, bevacizumab at the same
molar ratios formed high molecular weight complexes with
VEGF165, in agreement with earlier published work [21].
When the affinity of these observed high molecular weight
complexes to high- and low-affinity Fcc receptors was
investigated, we demonstrated that bevacizumab, when
bound to either VEGF121 or VEGF165 at equal molar ratios
(*1 lM), had drastically increased t1/2 values, ranging
from *threefold for the FccRI receptor to *177-fold
increase for the low-affinity FccRIIb receptor, compared to
bevacizumab alone. In contrast, aflibercept in complex
with VEGF121 or VEGF165 at equal molar ratios (*1 lM)
showed no appreciable difference in t1/2 values relative to
aflibercept alone.
Through platelet activation studies, we showed that
when heparin was added to bevacizumab:VEGF complexes
Fig. 5 Heparin and neuropilin-
1 differentially block
bevacizumab cell surface
binding. Surface binding to
ARPE-19 (a) or HUVEC
(b) cells was evaluated in the
presence of soluble heparin and
recombinant human neuropilin-
1. Cells pre-seeded onto
collagen-coated 96-well plates
were incubated at 37 C for
30 min with serial dilutions of
soluble heparin or rhNRP-1 pre-
complexed with 10 nM
VEGF165. Bevacizumab was
added to the cells to give a final
concentration of 15 nM,
followed by a 1-h incubation at
37 C. Surface staining of
bevacizumab was detected by
incubation with A488 anti-hIgG
(green fluorescence) at 4 C.
Cells were washed, fixed with
4 % paraformaldehyde, and
incubated with a nucleic acid
counterstain (DAPI for ARPE-
19 or DRAQ5 for HUVEC, red
fluorescence) prior to analysis.




bar = 50 lm in (a) and 100 lm
in (b)
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(100–400 nM), marked aggregation of platelets was
observed. Heparin, in this context, allows for optimal
FccRIIa receptor clustering by bringing the beva-
cizumab:VEGF complexes to the platelet surface [22].
However, when we increased the molar excess of beva-
cizumab (Cfourfold relative to VEGF165), the ability to
trigger platelet activation was lost, most likely due to the
ability of excess bevacizumab to decrease the size of the
multimeric complexes, reducing the avidity between
bevacizumab’s Fc domain and the FccRIIa receptor. In
contrast, preformed complexes of aflibercept and VEGF165
at equal molar ratios in the presence of heparin failed to
Fig. 6 In vitro binding of
bevacizumab and aflibercept to
NRP1.mFc and heparin–biotin
by SPR (Biacore) in the
presence of VEGF165. a Human
NRP1.mFc (155 RU) was
captured on an anti-mouse Fc-
coupled chip surface. The
histogram represents
bevacizumab and aflibercept at
concentrations of 500, 100, 10,
5, and 1 nM either alone or pre-
complexed at 1:1 molar ratio
with human VEGF121 or
VEGF165. b Heparin–biotin




aflibercept at concentrations of
500, 100, 10, 5, and 1 nM either
alone or pre-complexed at 1:1




binding to NRP1.mFc and
heparin at 5 nM are shown in
Supplementary Figure 7
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induce aggregation of human platelets. Consistent with
these results, serotonin release from platelets was not
observed for aflibercept:VEGF165 complexes but was
observed for bevacizumab:VEGF165 complexes. These
bevacizumab:VEGF165 complexes could form when sys-
temic or intravitreal levels of bevacizumab are low,
approaching the concentrations of endogenous VEGF.
To study the potential sequelae of bevacizumab’s
immune complex formation with VEGF, we incubated
bevacizumab:VEGF165 with either ARPE-19 cells or
HUVEC. At equimolar ratios of bevacizumab to VEGF165,
the complexes bound to the ARPE-19 cell surface. Indeed,
there was significant staining of the preformed beva-
cizumab:VEGF165 complexes at molar ratios from 4.5:1 to
0.06:1. These findings support the earlier work of Klettner
et al. [38] which showed that bevacizumab was taken up by
primary porcine RPE cells as assessed by confocal laser
scanning microscopy and flow cytometry. There was no
staining on the cell surface with bevacizumab complexed
with VEGF121, indicating that the heparin-binding domain
and/or the NRP1-binding site was required for immune
complex deposition. Very little cell surface staining was
observed on either ARPE-19 cell or HUVEC by afliber-
cept:VEGF165 complex over a wide range of molar ratios.
The binding of bevacizumab on the cell surface only
when in complex with VEGF165 but not VEGF121 points to
the involvement of the positively charged heparin-binding
domain found on VEGF165. The heparin-binding domain
confers diverse functions on VEGF165 [39], including
interaction with heparin and neuropilin present on the cell
surface. Binding of the bevacizumab:VEGF165 complex to
ARPE-19 cells was blocked by the addition of heparin but
not neuropilin. Conversely, binding of the beva-
cizumab:VEGF165 complex to HUVEC was blocked only
by the addition of neuropilin, illustrating that both heparin
or neuropilin can anchor these complexes to the cell
surface.
To determine whether these immune complexes could
form with endogenously produced VEGF, we added either
bevacizumab or aflibercept to ARPE-19 cells after
Fig. 7 Cell surface binding of bevacizumab is directly proportional
to endogenous VEGF165 concentration. ARPE-19 cells, cultured on
human fibronectin-coated coverslips in six-well plates, were treated
with equimolar concentration (1.68 lM) of bevacizumab, aflibercept,
or hFc for 3 days starting from different time points (Day 2, 4, 9, and
14) followed by immunofluorescence staining of cell surface-bound
inhibitor (red fluorescence, detected with mouse antihuman IgG Fc-
specific, and secondary Ab, goat anti-mouse IgG-Alexa flour 594.
Nuclei were counterstained with DAPI in blue). Cells and culture
media at various culture times (Days 2, 6, 9, and 28) were collected
for next-generation sequencing and ELISA of VEGF expression
levels. Cells treated with bevacizumab (a–d) showed an increased cell
surface binding in confluent ARPE-19 cell culture, coincident with
the upregulation of VEGF expression (m, n). Cells treated with
aflibercept (e–h) or control protein hFc (i–l) showed minimal binding
at all time points. Scale Bar = 50 lm
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allowing VEGF production to proceed over various time
periods (2, 4, 9, and 14 days). After quantifying VEGF
levels using both ELISA and next-generation sequencing, it
was clear that bevacizumab cell surface staining correlated
with the levels of VEGF produced. As in the studies using
exogenous VEGF, the addition of aflibercept to ARPE-19
cells containing different levels of VEGF did not result in
detectable cell surface staining.
In conclusion, we have demonstrated that bevacizumab
and aflibercept can exhibit strikingly different binding
stoichiometries with VEGF. When the molar concentration
of bevacizumab is within approximately tenfold that of
VEGF, two molecules of bevacizumab can bind to each
VEGF dimer via one of its two Fab arms, leaving the
second Fab arm on each bevacizumab free to bind another
VEGF dimer. This binding stoichiometry promotes the
formation of large, multimeric complexes of bevacizumab
which exhibit significantly enhanced binding affinity
toward low-affinity Fcc receptors. Moreover, the heparin-
and neuropilin-binding sites of VEGF165 are not occluded
when bound to bevacizumab, such that heparin/neuropilin-
mediated cell surface binding is also enhanced. That large
multimeric complexes of bevacizumab:VEGF165 exhibit
enhanced binding to both heparin/neuropilin and low-
affinity Fc receptors on cell surfaces underlies the ability of
these complexes to promote platelet aggregation and acti-
vation. In contrast, each aflibercept molecule forms a
homogenous 1:1 complex with each VEGF dimer at all
molar ratios of aflibercept:VEGF tested. This 1:1 binding
stoichiometry does not enhance binding to heparin or
neuropilin on cell surfaces. In addition, 1:1 afliber-
cept:VEGF complexes do not bind low-affinity Fcc
receptors more avidly than unbound aflibercept or mono-
meric IgG1, or cause platelet aggregation and activation.
While there is no evidence to link the reported higher
gastrointestinal disorders and the mechanism by which
bevacizumab binds VEGF, we have shown that differences
in binding at high molar ratios can be directly correlated to
differences in Fcc receptor binding, cell surface binding,
and platelet activation.
Materials and methods
Multi-angle laser light scattering detection coupled
to size exclusion chromatography (SEC–MALLS)
The SEC–MALLS system comprised an Agilent 1200
Series HPLC system equipped with an ultraviolet (UV)
diode array detector coupled to a Wyatt Technology
MiniDawn TREOS laser light scattering (LS) detector and
an Optilab REX differential refractometer (RI) detector
(Santa Barbara, CA). The detectors were connected in
series in the following order: UV–LS–RI. LS and RI
detectors were calibrated according to the instructions
provided by Wyatt Technology.
Complexes comprising 20 lM VEGF inhibitor
(aflibercept [Regeneron] or bevacizumab [Roche]) and 100
lM VEGF165 (Regeneron, produced in CHO cells) were
prepared separately and incubated for 12 h at ambient
temperature to form 1:5 molar ratio inhibitor:ligand com-
plexes. Similarly, 5:1 inhibitor:ligand complexes were
prepared with 100 lM VEGF inhibitor and 20 lM
VEGF165. Complexes comprising PlGF-2 (Regeneron) and
VEGF inhibitor (aflibercept or bevacizumab) were pre-
pared in the same manner as the inhibitor:VEGF165 com-
plexes. Appropriate amounts of unbound inhibitor (20 lM)
or ligand (40 lM) were also injected separately into a pre-
equilibrated Superose 12 10/300 GL (GE Healthcare) size
exclusion column. The mobile phase was 10 mM phos-
phate, 500 mM NaCl, pH 7.0 with a flow rate of 0.3 mL/
min. Molar masses of free ligands, free inhibitor, and
inhibitor:ligand complexes were determined using ASTRA
software (Wyatt Technology) as previously described [40].
The standard deviation calculated from bovine serum
albumin (BSA) standard samples was within 2 % in dif-
ferent SEC–MALLS experiments.
Surface plasmon resonance kinetic binding assay
SPR experiments were performed on a Biacore 3000
instrument using a dextran-coated (CM4 or CM5) chip at
25 C. The running buffer was filtered HBS-T (10 mM
Hepes, 150 mM NaCl, 3.4 mM EDTA, 0.05 % polysorbate
20, pH 7.4). A capture sensor surface was prepared by
covalently immobilizing anti-histidine monoclonal anti-
body (His capture kit, GE Healthcare), anti-mouse Fc
(Mouse antibody capture kit, GE Healthcare), or neutra-
vidin (Thermo Fisher Scientific Inc.) to the chip surface
using 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide
hydrochloride/N-hydroxysuccinimide (EDC/NHS) cou-
pling chemistry. Following surface activation, capturing
reagents in coupling buffer (0.1 M acetate buffer, pH 4.5)
were injected over the activated chip surface until the
binding signals in resonance unit (RU) reached about
3500 RU for the anti-histidine monoclonal antibody sur-
face, 1500 RU for the anti-mouse Fc polyclonal antibody,
and 5000 RU for the neutravidin, respectively. The sur-
faces were then washed and treated with 10 mM glycine–
HCl at pH 1.5 to remove uncoupled residual proteins. The
various his-tagged or myc–myc His-tagged Fcc receptor
family members, mFc-tagged human NRP1 (Regeneron),
and biotinylated heparin (Sigma-Aldrich) were injected
over the corresponding capture surfaces to a low density at
approximate 200 RU in the running buffer with a con-
centration range between 5 and 10 lg/mL. The His-tagged
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FccRIIAR131, FccRIIB/C, FccRIIIB, and FccRI were pur-
chased from R&D Systems, and myc–myc His-tagged
FccRIIIAF176, and FccRIIIAV176 were generated at
Regeneron.
Following the capture step, bevacizumab (Roche) or
aflibercept (Regeneron) solutions with and without
equimolar concentrations of VEGF165 (Regeneron) or
VEGF121 (R&D Systems, produced in E. coli) (from
1.0 lM to 31.25 nM in a twofold serial dilutions) were
individually injected over the various Fcc receptor, human
NRP1.mFc, and biotin–heparin surfaces, and the real-time
binding signals were recorded. The specific binding sen-
sorgrams were obtained using a double-referencing pro-
cedure as described by Myszka et al. [41] by subtracting
the binding signal on the blank capture surface and sample
buffer run. The binding data were then processed and
analyzed using Scrubber software (version 2.0, BioLogic
Software), and the dissociation rate constant (kd) and dis-
sociation half-life t1/2 were calculated.
Platelet aggregation
Washed platelet preparation
Platelet concentrate was obtained from the NY Blood
Center and used before expiration. Washed platelet
suspensions were prepared from pooled platelets
obtained from citrated phosphate dextrose blood using
the method of Cazenave et al. [42]. Approximately
20 mL of platelet concentrate was centrifuged (2200g,
25 C) for 12 min. The supernatant was removed, and
20 mL of modified Tyrode’s buffer (137 mM NaCl,
2.7 mM KCl, 12 mM NaHCO3, 0.42 mM NaH2PO4,
2 mM MgCl2, 5 mM HEPES, 5.55 mM dextrose, pH 6.2)
containing 1.5 U/mL apyrase Grade VII (Sigma-Aldrich)
and 0.5 lM prostacyclin I2 (Cayman Chemical) was
added. The platelets were resuspended and allowed to
rest for 10 min at 37 C. Following this, another 0.5 lM
of prostacyclin I2 was added, and the platelets were
centrifuged (1900g, 25 C) for 8 min. The supernatant
was removed, and another 20 mL of modified Tyrode’s
buffer containing 1.5 U/mL apyrase Grade VII and
0.5 lM prostacyclin I2 was used to resuspend the pla-
telets. The platelets were allowed to rest for 10 min at
37 C. After this second wash step, 0.5 lM of prosta-
cyclin was added and the platelets were centrifuged
(1900g, 25 C) for 8 min. The supernatant was removed,
and 40 mL of Tyrode’s buffer containing calcium (Ty-
rode’s buffer with 2 mM CaCl2, pH 7.35) was added.
The platelets were resuspended and diluted to 300,000
cells/lL using the same buffer. Using this procedure, the
washed platelet suspension was stable for 4 h when
stored at 37 C.
Platelet aggregometry
Platelet aggregation was monitored at an absorbance of
600 nm using a Beckman DU7400 spectrophotometer fit-
ted with a homemade thermostatic stirring chamber. In
typical experiments, 1.8 mL of platelets was added to
3-mL plastic cuvettes containing a stir bar designed for
spectrophotometer cells (Fisher Scientific). The platelets,
under constant stirring, were allowed to reach thermo-
equilibrium for 5 min. Then, 100 lL of PBS containing
agonist (epinephrine, Sigma-Aldrich) and unfractionated
heparin (Sigma-Aldrich) was added. After 1 min, data
collection was begun and an additional 100 lL of PBS
containing the bevacizumab:VEGF or aflibercept:VEGF
complex was added. Platelet aggregation was typically
monitored for 10–15 min. Plots of percent aggregation
were calculated by taking the initial average absorbance of
the platelets (*1.3–1.4 AU) as 0 % aggregation and an
absorbance of zero as 100 % aggregation.
Serotonin release assay
In vitro platelet activation was studied using a serotonin
release model described by Meyer et al. [22]. Human
platelets were loaded with 14C-serotonin (PerkinElmer),
then washed, and incubated at 22 C with the test complex
for 1 h under constant stirring. Released serotonin was
counted in the supernatant and expressed as a percentage of
the total serotonin loaded into the platelets. To create
bevacizumab:VEGF165 or aflibercept:VEGF165 complexes,
VEGF165 (R&D Systems) and bevacizumab (Roche) or
aflibercept (Regeneron) were coincubated in PBS at
equimolar concentrations (2.5 lM) for 15 min at 22 C.
The complex was then added to 14C-serotonin-loaded
platelets in the presence of heparin (Sigma-Aldrich).
Complex was added to platelets to obtain a final concen-
tration of 0.1, 0.2, 0.5, or 1 lM and tested in the presence
of a range of unfractionated heparin concentrations (0.5-
500 lg/mL).
Assessment of platelet-activating activity in FccRIIa
transgenic mice
Experimental animals
B6;SJL-Tg (FccRIIa)11Mkz (FCGR2A) mice were
obtained from Jackson Laboratories and bred in the Animal
Care Facility at Florida Hospital, Orlando, in compliance
with approved Institutional Animal Care and Use Com-
mittee (IACUC) guidelines and protocols. All experiments
were performed in 8- to 15-week-old mice weighing
between 16 and 20 g. All animals were genotyped and
confirmed positive for the FccRIIa transgene according to
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Jackson Laboratories PCR Protocols. Some animals were
injected with PBS (vehicle containing no immune complex
components) in order to establish baseline platelet counts,
as described below.
Mouse blood sampling, platelet counting, and intravenous
injection procedures
For IV injections, mice were immobilized in a standard
restrainer and warmed using a heat lamp for 2 min to dilate
the tail vein. Immune complexes were preassembled by
mixing antibody ? antigen at a 1:1 molar ratio (126 lg
M90 [Florida Hospital] ? 45 lg CD154 [Peprotech], or
35 lg VEGF [Peprotech, produced in E. coli] ? either
126 lg bevacizumab [Genentech] or 92 lg aflibercept
[Regeneron] ± heparin [Sigma-Aldrich] in PBS). Immune
complexes were injected slowly in a 200-lL bolus into the
lateral tail vein. Animals were then removed from their
restraining device and placed in an open observation cage
for monitoring. Ten minutes after reagent injection, mice
were anesthetized by isoflurane inhalation. Approximately
500 lL of blood was collected by cardiac puncture via
27-gauge needles into syringes containing 50 lL of acid
citrate dextrose (ACD). The blood was immediately placed
in a polypropylene collection tube containing 50 lL of
ACD, and platelet counts were measured using an auto-
mated cell counter. Platelet counts were adjusted for citrate
solution volume. All animals were observed for signs of
distress throughout the test procedure, specifically for rapid
shallow breathing, hunched posture, and signs of decreased
or dysfunctional locomotor activity. The combination of
these symptoms is often referred to as a ‘‘shock’’ or
‘‘thrombotic’’ phenotype. The observation of such symp-
toms was recorded along with platelet counts per animal.
Together, platelet counts and signs of physical distress
constitute the primary data in this animal model.
Histochemical analysis of lung sections
Following blood draws, animals were killed by CO2
inhalation. Mouse lungs were dissected en bloc from
isofluorane-anesthetized animals not subjected to cardiac
puncture. Lungs were rinsed in PBS and immediately
placed in 10 % formalin–PBS for at least 24 h prior to
paraffin embedding. Histopathology laboratory technicians
cut some distance into the paraffin block (lung tissue) prior
to initial sectioning. Cut sections (2 lm thick) were
deparaffinized and rehydrated and then processed by an
automated H&E staining process at the Florida Hospital
main Histopathology Laboratory. Lungs sections from each
group were analyzed microscopically for evidence of
thrombosis by two independent observers. Also, reference
lungs were harvested from baseline animals and processed
identically as described above. Fields were captured from
each section using a Nikon Eclipse 80i upright microscope
equipped with Plan Fluor objectives (109, NA = 0.3, DIC;
209, NA = 0.5, DIC; 409, NA = 0.75, DIC; and 609,
NA = 0.85, not DIC), a DC-Fi1 digital camera, and a DS-
L2 image capture device. The eyepiece and camera had a
collective magnification of 109, resulting in final image
magnifications of 100, 200, 400, or 6009, respectively,
with each objective lens. The capture device was activated
by pressing a ‘‘Capture’’ button. The image capture device
was set by integrated software to automatically adjust for
white balance. Observers were instructed to adjust lamp
intensity and stage diaphragm (aperture) settings as needed
per image; thus, variations in brightness, contrast, and color
hue may be observed in some images. Images were con-
verted from TIF format to JPEG and processed in Adobe
Photoshop Elements (v8) without region-specific modifi-
cations (i.e., all changes were global, and no region-
specific change was made to any image).
Statistical analysis
Statistical analysis was performed using SigmaPlot v11
software. The distributions of experimental data sets for
mouse platelet counts were determined by normal proba-
bility analysis. All groups were found to be normally dis-
tributed and of equal variance. Therefore, differences
between groups were analyzed by one-way ANOVA using
the raw data (rather than the means and standard devia-
tions). The statistical test used was the multiple compar-
isons versus control group Bonferroni t test
(alpha = 0.050:1.000).
Cell surface binding of VEGF inhibitors to ARPE-19
cells in the presence of exogenous VEGF
Confluent ARPE-19 cells (ATCC) on 96-well collagen-
coated plates (Greiner CellCoat) were incubated with 5 nM
bevacizumab (Roche), or aflibercept (Regeneron) alone or
in the presence of 10 nM VEGF165 (Regeneron) or 10 nM
VEGF121 (R&D Systems) at 37 C for 1 h. Cell surface-
bound VEGF inhibitors were detected with Alexa 488 goat
antihuman IgG (H ? L) Fab fragment (A488-anti-hIgG,
Jackson Immunoresearch), followed by fixation with 4 %
paraformaldehyde and counterstaining with DAPI. Fluo-
rescence was detected using a Molecular Devices
ImageXpress Micro XL High-Content Imaging System
equipped with a Nikon 109 Plan Fluor WD objective lens
(NA 0.30). All images were acquired with a Molecular
Devices 1.4 megapixel cooled CCD camera using
MetaXepress High-Content Image Acquisition and
Analysis Software and analyzed using PerkinElmer
Columbus Image Data Storage and Analysis System.
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Figures were made in Adobe Photoshop. No adjustments
were made to the original images.
Cell surface binding of VEGF inhibitors to HUVEC
in the presence of exogenous VEGF
HUVEC (Vec Technologies) were seeded into 96-well
collagen-coated plates (Greiner CellCoat) at a concentra-
tion of 20,000 cells/well in complete medium (Vec Tech-
nologies) and incubated overnight at 37 C. The cells were
washed 29 in PBS, followed by sequential addition of
10 nM VEGF165 or 10 nM VEGF121 and serial dilutions of
bevacizumab or aflibercept in assay medium (2 % FBS in
PBS). Control wells containing ligand, bevacizumab, or
aflibercept alone were also evaluated. After a 2-h incuba-
tion at 37 C, the cells were washed 29 in PBS. The
presence of cell-bound inhibitor was determined by incu-
bation with 1 lg/mL A488-anti-hIgG (Jackson) in assay
medium for 30 min at 4 C. The cells were washed 29 in
PBS and then fixed in 3.7 % formaldehyde in PBS for
20 min at room temperature followed by a final wash with
PBS. Cells were counterstained with Draq5 (Cell Signaling
Technologies) following the manufacturer’s instructions
and imaged using Molecular Devices ImagExpress Micro
XL High-Content Imaging System equipped with a Nikon
20X S Plan Fluor EL WD objective lens (NA 0.45; WD
8.2–6.9 mm). All images were acquired with a Molecular
Devices 1.4 megapixel cooled CCD camera using
MetaXepress High-Content Image Acquisition and
Analysis Software and analyzed using PerkinElmer
Columbus Image Data Storage and Analysis System. Fig-
ures were made in Adobe Photoshop. No adjustments were
made to the original images.
Heparin or neuropilin-1 blockade of VEGF165
bridging in ARPE-19 cells
ARPE-19 cells (ATCC) were incubated for 30 min with
serial dilutions of soluble heparin (Sigma-Aldrich; starting
from 1000 nM, 1:2) or rhNRP-1-mFc (Regeneron; starting
from 100 nM, 1:2) pre-incubated with 10 nM VEGF165
(Regeneron). Bevacizumab was added to the cells (final
concentration 10 nM), followed by a 1-h incubation at
37 C. Surface staining of bevacizumab was detected with
A488-anti-hIgG (Jackson Immunoresearch), followed by
fixation in 4 % paraformaldehyde and counterstaining with
DAPI. Fluorescence was detected by a Molecular Devices
ImageXpress Micro XL High-Content Imaging System
equipped with a Nikon 20x Plan Fluor ELWD objective
lens (NA 0.45; WD 8.2–6.9 mm). All images were
acquired with a Molecular Devices 1.4 megapixel cooled
CCD camera using MetaXepress High-Content Image
Acquisition and Analysis Software and analyzed using
PerkinElmer Columbus Image Data Storage and Analysis
System. Figures were made in Adobe Photoshop. No
adjustments were made to the original images.
Heparin or neuropilin-1 blockade of VEGF165
bridging in HUVEC
Serial dilutions of heparin (Sigma-Aldrich) or rhNRP-1-
mFc (Regeneron) were premixed with 10 nM VEGF165.
The mixture was then added to HUVEC plated as
described above and incubated for 30 min at 37 C. A
constant concentration of 15 nM bevacizumab was then
added to cells, followed by a 1-h incubation at 37 C.
The cells were washed, detected with 1 lg/mL
A488anti-hIgG (Jackson), counterstained with Draq5
(Cell Signaling Technologies), and imaged using
Molecular Devices ImagExpress Micro XL High-Con-
tent Imaging System equipped with a Nikon 20x S Plan
Fluor EL WD objective lens (NA 0.45; WD
8.2–6.9 mm). All images were acquired with a Molecu-
lar Devices 1.4 megapixel cooled CCD camera using
MetaXepress High-Content Image Acquisition and
Analysis Software and analyzed using PerkinElmer
Columbus Image Data Storage and Analysis System.
Figures were made in Adobe Photoshop. No adjustments
were made to the original images.
Cell surface binding of VEGF inhibitors to APRE-19
cells in the presence of endogenous VEGF
ARPE-19 cells (ATCC), cultured on human fibronectin
(Corning)-coated coverslips in six-well plates, were treated
with equimolar concentration (1.68 lM) of bevacizumab
(Roche), aflibercept (Regeneron), or hFc (Regeneron) for
3 days starting from different time points (Days 2, 4, 9, and
14) followed by immunofluorescence staining of cell sur-
face-bound inhibitor [red fluorescence, detected with
mouse antihuman IgG Fc-specific, and secondary Ab, goat
anti-mouse IgG(h ? L)-Alexa Fluor 594 (Life Technolo-
gies)]. Nuclei were counterstained with DAPI in blue.
Fluorescence was detected in ProLong Gold antifade
reagent (Life Technologies) using a Nikon Eclipse 80i
microscope equipped with a Nikon Plan APO 20x objective
lens (NA 0.75). All images were acquired with a Diag-
nostic Instruments Spot Camera using Diagnostic Instru-
ments Spot 4.7 software and analyzed using PerkinElmer
Columbus Image Data Storage and Analysis System. Fig-
ures were made in Adobe Photoshop. The photomerge
function was used to merge blue and red channel images.
Cells and culture media at various culture times (Days 2,
6, 9, and 28) were collected for next-generation sequencing
(Illumina Hiseq 2000) and ELISA (R&D Systems) of
VEGF expression levels.
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